The purpose of this study is to use the Decipher risk score (The Decipher risk score is determined by testing the prostate tumor tissue from your biopsy for many different genes that all together indicate the risk of your cancer spreading.) to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness.
Learn more about the NRG-GU010 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
